Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Stay well-informed and make prudent decisions using our Ratings Table. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, ...

Previously, Dr. Gotwals led program management at Altus Pharmaceuticals and spent 12 years at Biogen Idec in research, development and program management. He is currently a Partner at Red Sky ...

Stay informed and make well-considered decisions with our Ratings Table. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug ...

Gotwals brings over 30 years of biopharmaceutical experience, including roles at Novartis Institutes for BioMedical Research and Biogen Idec, and currently serves as a partner at Red Sky Partners.

His career also includes clinical development roles at Biogen Idec and Amgen, as well as clinical and academic appointments at the Mayo Clinic, Scripps Mercy Hospital and The Scripps Research ...

Compr Ophthalmol Update. 2007;8(1):39-49. Disclosure: Dr. Balcer has served as a consultant for development of visual outcomes for trials for Biogen Idec, Merck Serono, Sirtris Pharmaceuticals ...